85/100 · Critical
Manufactured by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Doxycycline Hyclate Adverse Events: High Serious Reaction Rate
180,624 FDA adverse event reports analyzed
Last updated: 2026-05-12
DOXYCYCLINE HYCLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.. Based on analysis of 180,624 FDA adverse event reports, DOXYCYCLINE HYCLATE has a safety score of 85 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for DOXYCYCLINE HYCLATE include DRUG INEFFECTIVE, NAUSEA, OFF LABEL USE, FATIGUE, RASH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DOXYCYCLINE HYCLATE.
Doxycycline Hyclate has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 180,624 adverse event reports for this medication, which is primarily manufactured by Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc..
The most commonly reported adverse events include Drug Ineffective, Nausea, Off Label Use. Of classified reports, 72.9% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. High rate of serious reactions including kidney and respiratory issues.
Multiple gastrointestinal and dermatological reactions are common. Significant number of reports involve drug ineffectiveness and hyper-sensitivity.
Patients taking Doxycycline Hyclate should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Doxycycline Hyclate may interact with other antibiotics, causing increased risk of adverse reactions. Patients should avoid concurrent use of nephrotoxic drugs. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Doxycycline Hyclate received a safety concern score of 85/100 (high concern). This is based on a 72.9% serious event ratio across 63,725 classified reports. The score accounts for 180,624 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 36,522, Male: 21,322, Unknown: 133. The most frequently reported age groups are age 44 (1,364 reports), age 43 (1,126 reports), age 59 (951 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 63,725 classified reports for DOXYCYCLINE HYCLATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Doxycycline Hyclate may interact with other antibiotics, causing increased risk of adverse reactions. Patients should avoid concurrent use of nephrotoxic drugs.
If you are taking Doxycycline Hyclate, here are important things to know. The most commonly reported side effects include drug ineffective, nausea, off label use, fatigue, rash. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Inform your healthcare provider about any pre-existing conditions, especially kidney or respiratory issues, before starting Doxycycline Hyclate. Monitor for signs of allergic reactions and report them immediately. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor Doxycycline Hyclate for safety. Healthcare providers should report any adverse events to the FDA's MedWatch program.
The FDA has received approximately 180,624 adverse event reports associated with Doxycycline Hyclate. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Doxycycline Hyclate include Drug Ineffective, Nausea, Off Label Use, Fatigue, Rash. By volume, the top reported reactions are: Drug Ineffective (4,954 reports), Nausea (4,734 reports), Off Label Use (4,410 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Doxycycline Hyclate.
Out of 63,725 classified reports, 46,438 (72.9%) were classified as serious and 17,287 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Doxycycline Hyclate break down by patient sex as follows: Female: 36,522, Male: 21,322, Unknown: 133. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Doxycycline Hyclate adverse events are: age 44: 1,364 reports, age 43: 1,126 reports, age 59: 951 reports, age 68: 923 reports, age 63: 917 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Doxycycline Hyclate adverse event reports is Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Doxycycline Hyclate include: Diarrhoea, Pain, Dyspnoea, Headache, Vomiting. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Doxycycline Hyclate to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Doxycycline Hyclate has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. High rate of serious reactions including kidney and respiratory issues.
Key safety signals identified in Doxycycline Hyclate's adverse event data include: High incidence of kidney-related issues (Chronic Kidney Disease, Acute Kidney Injury).. Multiple reports of respiratory issues (Pneumonia, Dyspnoea).. Significant number of skin reactions (Rash, Urticaria).. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Doxycycline Hyclate may interact with other antibiotics, causing increased risk of adverse reactions. Patients should avoid concurrent use of nephrotoxic drugs. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Doxycycline Hyclate.
Inform your healthcare provider about any pre-existing conditions, especially kidney or respiratory issues, before starting Doxycycline Hyclate. Monitor for signs of allergic reactions and report them immediately.
Doxycycline Hyclate has 180,624 adverse event reports on file with the FDA. Multiple gastrointestinal and dermatological reactions are common. The volume of reports for Doxycycline Hyclate reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor Doxycycline Hyclate for safety. Healthcare providers should report any adverse events to the FDA's MedWatch program. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
The following drugs share commonly reported adverse reactions with DOXYCYCLINE HYCLATE:
Drugs related to DOXYCYCLINE HYCLATE based on therapeutic use, drug class, or shared indications: